LONDON— Intraoperative radiotherapy given at the time of lumpectomy was found to be ‘non-inferior’ to the use of conventional post-operative whole breast external beam radiotherapy and had equivalent breast cancer specific mortality but fewer non-cancer deaths. This is according to findings from the TARGIT-A study by researchers in the United Kingdom, Germany and Australia with five-year follow up data published in the Lancet. The authors give reassurance that with a ‘risk adapted’ strategy — in which patients receiving intra-operative therapy were given supplementary external beam radiation if the operation revealed they were at high risk — is a safe and effective alternative to the conventional approach and could not only benefit patients but also reduce costs. Investigators Professor Jayant S Vaidya PhD and Professor Michael Baum MB ChB FRCS describe their findings and discuss the clinical implications.
You may also like...
- Previous story Colorectal cancer screening: survey of 11 European countries finds big mortality benefit
- Next story Disease-free survival doubles for patients treated with immunoconjugate TDM-1 for their HER-2 positive metastatic breast cancers
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014